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Midterm outcomes of the Zenith Renu AAA
Ancillary Graft
Jeffrey Jim, MD,a Brian G. Rubin, MD,a Patrick J. Geraghty, MD,a Samuel R. Money, MD, MBA,b and
Luis A. Sanchez, MD,a St. Louis, Mo; and Scottsdale, Ariz
Objective: The Zenith Renu abdominal aortic aneurysm (AAA) Ancillary Graft (Cook Medical Inc, Bloomington, Ind)
provides active proximal fixation for treatment of pre-existing endografts with failed or failing proximal fixation or seal.
The purpose of this study was to evaluate the midterm outcomes of treatment with this device.
Methods: From September 2005 to November 2006, a prospective, nonrandomized, multicenter, postmarket registry was
utilized to collect physician experiences from 151 cases (89 converters and 62 main body extensions) at 95 institutions.
Preoperative indications and procedural and postimplantation outcomes were collected and analyzed. Technical success
and clinical success were determined as defined by the Society of Vascular Surgery reporting standards.
Results: Patients were predominantly male (87%) with a mean age of 77 years. The interval between the original endograft
implantation to Renu treatment was 43.4  18.7 months. The indications for treatment were endoleak (n  111),
migration (n 136), or both (n 94). Technical success was 98.0% with two cases of intraoperative conversion and one
case of persistent type IA endoleak. The median follow-up for the cohort was 45.0 months (range, 0-56 months;
interquartile range, 25.0 months). Overall, 32 cases had treatment failures that included at least one of the following:
death (n 5), type I/III endoleak (n 18), graft infection (n 1), thrombosis (n 1), aneurysm enlargement>5 mm
(n 9), rupture (n 4), conversion (n 9, with 7 after 30 days), and migration (n 1). Overall, the clinical success for
the entire cohort during the follow-up period was 78.8% (119/151).
Conclusions: The postmarket registry data confirm that the Zenith Renu AAA Ancillary Graft can be used to treat
endovascular repairs that failed due to proximal attachment failures. The salvage treatment with the Renu device had high
technical success rate and resulted in clinical success in a majority of patients (78.8%). While failed endovascular repairs
can be salvaged, a clinical failure in one of five patients still emphasizes the importance of patient and device selection
during initial endovascular aneurysm repair to ensure durable success. ( J Vasc Surg 2011;54:307-15.)
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iEndovascular abdominal aortic aneurysm (AAA) repair
(EVAR) was first introduced by Parodi and Volodos in
1991.1,2 It has since gained wide acceptance as a safe and
effective treatment modality for infrarenal AAAs. In the
United States, over 50% of all AAAs are currently treated
with EVAR,3 and multiple clinical trials have confirmed its
perioperative benefits.4-6 However, the long-term survival
benefits of EVAR compared with traditional open repair
remain uncertain. Furthermore, EVAR has been associated
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doi:10.1016/j.jvs.2010.12.058ith an increased rate of graft-related complications and
econdary interventions.4,7
Successful aneurysm exclusion with EVAR depends upon
natomical suitability, appropriate device selection, and
roper positioning of the endograft. A major complication of
VAR is the development of proximal attachment failure,
hich can lead to endograft migration with resultant type I
ndoleak, aneurysm growth, and possibly rupture. Migration
s a potential complication with all commercially available
ndografts. When a graft is used within the guidelines of the
anufacturer’s instructions for use (IFU), excellent long-
erm results with low rates of migration can be obtained.
owever, as the use of EVAR is extended to patients with
hallenging anatomy beyond the scope of the IFU, there is a
egative impact on late results.8,9
The Zenith Renu AAA Ancillary Graft (Cook Medical
nc, Bloomington, Ind) was approved by the United States
ood and Drug Administration (FDA) in June 2005. It is an
ndovascular aortic ancillary device that acts as a “bailout”
evice for endovascular salvage by providing active proximal
xation for pre-existing endovascular aortic grafts with failed
r failing proximal fixation or seal, especially in patients who
re not candidates for open surgical repair. The graft is avail-
ble in two configurations: a main body extension and a
onverter. The main body extension is an aortic cuff with
ransrenal fixation. The converter also has transrenal fixation,
ut extends distally into an iliac artery to achieve an aortouni-
liac (AUI) repair. As such, the use of the converter requires
oncurrent femoro-femoral bypass and contralateral iliac ar-
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August 2011308 Jim et altery occlusion. The purpose of this study was to evaluate the
midterm outcomes of treatment with the Zenith Renu AAA
Ancillary Graft using data from a prospective, multicenter,
postmarket registry.
METHODS
Study design. Between September 9, 2005 and No-
vember 9, 2006, a prospective, nonrandomized, multi-
center, postmarket registry was used to collect physician
experiences with the Renu device. Data collection was
prospectively planned for up to 5 years after device implan-
tation. Information collected by the treating physicians
included preoperative, procedural, and follow-up visit data
from imaging and clinical evaluations. An independent
Clinical Events Committee (CEC) and Data Safety Moni-
toring Board were established. All available imaging was
independently evaluated by an angiographic core labora-
tory (Cleveland Clinic, Cleveland, Ohio). All registry data
were collected, organized, stored, and statistically evalu-
ated by MED Institute, Inc (West Lafayette, Ind). Authors
of this study had complete access to the original registry
data. The registry is ongoing, but for the purpose of this
study, only data as reported through April 13, 2010 were
utilized for the analyses.
Device. The Zenith Renu AAA Ancillary Graft is indi-
cated for secondary endovascular intervention in patients
who received prior endovascular repair of infrarenal ab-
dominal aortic or aortoiliac aneurysms in which there is
inadequate proximal fixation or seal. Additional details
regarding the IFU as well as the device description have
previously been reported (Appendix, online only).10
Implantation procedure. Before implantation, all
cases were reviewed by a member of the physician review
committee to ensure anatomic suitability and that patients
met the IFU for the device. Options for treatment were
then presented to the treating physician. The choice of final
device configuration was ultimately left to the discretion of
the implanting physician. Device delivery was performed in
accordance with the IFU. Use of a converter device, in
most patients, required a femoro-femoral bypass and occlu-
sion of the contralateral iliac artery.
Definitions. In compliance with the reporting stan-
dards recommended by the Society of Vascular Surgery
(SVS) and the American Association for Vascular Surgery,
technical success was defined as successful introduction and
deployment of the endograft without the need for conver-
sion and without mortality, type I or III endoleak, or graft
limb occlusion within the first 24 hours. Clinical success
required successful deployment of the endovascular device
without aneurysm-related death, type I or III endoleak,
graft infection or thrombosis, aneurysm expansion, aneu-
rysm rupture, or conversion to open repair. In the absence
of aneurysm expansion, type II endoleaks were not consid-
ered clinical failures. All deaths that occurred within 30 days
of the operative procedure were classified as procedure-
related. Deaths that occurred after 30 days were considered
late deaths. Aneurysm-related deaths were defined as all
deaths due to aneurysm rupture, primary or secondary crocedure, or surgical conversion.11 Migration was defined
smovement (antegrade or retrograde)10mm relative to
natomic landmarks identified on the first postoperative
omputed tomography scan. Endoleak was defined as per-
istent blood flow in the aneurysm sac outside of the
ndograft, which could be due to inadequate seal at either
he proximal or distal ends of the graft or attachment zones
type I), retrograde perfusion via collateral vessels (type II),
isconnection of device components or device fabric tear
r disruption (type III), and high porosity graft material
type IV).
Statistical analysis. Statistical analysis was performed
n the prospectively collected data using SAS 9.1 software
SAS Institute, Inc, Cary, NC). Descriptive data are pre-
ented as mean  standard error. Fisher exact tests and
aplan-Meier estimations were performed where appropri-
te, and a value of P  .05 was considered statistically
ignificant.
ESULTS
A total of 151 cases at 95 institutions were enrolled into
he registry. There were 131 (87%)males, and themean age
as 77 years for the entire cohort. The indications for
reatment included migration in 136 cases (90.1%), en-
oleak(s) in 111 cases (73.5%), and presence of both mi-
ration and endoleak(s) in 94 cases (62.3%). Device integ-
ity failure (eg, stent fracture or breakage, graft tear,
omponent separation), kink, or occlusion were reported in
onjunction with migration or endoleak in 15 cases. The
neuRx (Medtronic Vascular, Santa Rosa, Calif) device
ccounted for 83.4% of all pre-existing endovascular aortic
rafts treated with the Renu device (Table I). The median
ime interval between implantation of the original devices
nd Renu implantation was 41.0 months (interquartile
ange, 28.0 months).
For Renu treatment outcomes, the median follow-up
or the entire cohort was 45.0 months (range, 0-56
onths; interquartile range, 25.0 months). Data were
vailable for 100% of patients at 30 days, 97.8% of patients
t 12 months, 84.3% of patients at 24 months, 69.7% of
atients at 36 months, and 64.0% of patients at 48 months.
Technical success. Of 151 cases, 89 (59%) were
reated with a Renu converter and 62 (41%) with a Renu
ain body extension. Deployment of the Renu device was
uccessful in all cases. There were two cases of intraopera-
ive conversion to open repair. One patient with a proximal
ype I endoleak with associated migration of an AneuRx
evice was treated with a Renu converter, iliac occluder,
nd a Palmaz stent (Johnson& Johnson Corp, New Bruns-
ick, NJ). The patient required emergent conversion to
pen repair due to rupture of the aortic wall proximal to the
enu device. The patient did not survive the conversion. A
econd patient was treated with a Renu converter for a
roximal type I endoleak with associated migration of an
neuRx device. On completion angiography, a persistent
ype I endoleak was detected. No further endovascular
reatments were attempted; as the patient was considered a
andidate for surgery, the treating physician chose to con-
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Volume 54, Number 2 Jim et al 309vert the procedure to open repair. In addition, there was
one instance of a persistent type I endoleak. This patient
was treated with a Renu converter for proximal type I
endoleak, migration, and kink of an AneuRx device. A
proximal type I endoleak was identified at the end of the
procedure, but was not treated intraoperatively. The en-
doleak did not resolve with time and the patient was
successfully treated via conversion to open repair at 3
months post-Renu implantation. In all, the technical suc-
cess rate for the Renu devices was 98.0% (148 of 151
patients).
Aneurysm rupture. There were four aneurysm rup-
tures after Renu implantation. Three patients were treated
with Renu main body extensions for migrated AneuRx
devices. Preoperatively, physician peer reviewers suggested
that a Renu converter may be a better treatment option for
all three patients due to anatomic reasons. These included
severe angulation of the pre-existing endograft, infrarenal
aortic angulation, and significant infrarenal diameter
change. However, all ultimately had implantation of a main
body extension at the discretion of the treating physician.
These three ruptures were due to type III endoleaks/
separation between devices, and the patients were treated
with emergent open surgical repair. One patient was
treated at 12 months and survived. The other two were
treated at 12 months and 16 months, respectively, and did
not survive the conversion procedures. The fourth aneu-
rysm rupture occurred in a patient treated with a Renumain
body extension for migration and proximal type I endoleak.
At the 12-month follow-up, the patient was found to have
aneurysm expansion associated with a type II endoleak. The
patient declined further intervention, the aneurysm subse-
quently ruptured, and the patient expired 30 months after
Renu implantation. The Kaplan-Meier analysis estimated
that 55-month freedom from aneurysm rupture is 97.3%
(Fig 1).
Conversion. There were a total of nine instances of
conversion to open repair in the entire cohort (Table II). As
noted, two patients underwent intraoperative conversion at
the time of the Renu graft implantation, and one patient
underwent elective conversion at 3 months due to a persis-
Table I. Pre-existing endovascular grafts treated with the
Device treated Num
AneuRx (Medtronic Vascular, Santa Rosa, Calif) 126
Ancure (Abbot Vascular, Abbot Park, Ill) 9
Excluder (W. L. Gore, Flagstaff, Ariz) 6
Talent (Medtronic Vascular, Santa Rosa, Calif) 3
Vanguard (Boston Scientific, Natick, Mass) 2
Otherb 2
Fortron (Cordis Endovascular, Warren, NJ) 1
Lifepath (Baxter, Morton Grove, Ill) 1
Zenith (Cook Inc, Bloomington, Ind) 1
aThe implantation times for 10 AneuRx grafts, one Ancure graft, and one T
bHandmade graft (one aortouni-iliac, one bifurcated).tent proximal type I endoleak. As described above, three Tatients who presented with ruptured aneurysms under-
ent emergent conversion. Three additional instances of
onversion to open repair occurred more than 12 months
fter implantation of the Renu device. One conversion was
erformed at 19 months post Renu implantation due to a
uspected graft infection and resulted in successful open
epair with endograft explantation. The site reported that
he graft infection was related to the original endograft.
urthermore, core laboratory analysis of the preprocedure
maging (prior to Renu implantation) indicated that
tranding within the aneurysm sac was a possible indication
f infection of the pre-existing endograft. The second
onversion was performed at 30 months, following identi-
cation of a proximal type I endoleak during the 24-month
ollow-up time period. The patient underwent coil embo-
ization at 25 months and additional stenting at the graft
eck at 29 months. Both endovascular attempts to resolve
he endoleak were unsuccessful. The proximal type I en-
oleak was ultimately successfully treated with open repair.
th Renu AAA Ancillary Graft
Implantation time prior to Renu (month)a
) Median Quartile range n
) 40.0 25.5 116
59.0 13.5 8
36.5 34.0 6
38.5 1.0 2
96.0 0 2
75.0 20.0 2
44.0 0 1
38.0 0 1
15.0 0 1
graft were not provided.
ig 1. Kaplan-Meier curve of freedom from rupture in patients
reated with a Zenith Renu AAA Ancillary Graft.Zeni
ber (%
(83.4
(6.0)
(4.0)
(2.0)
(1.3)
(1.3)
(0.7)
(0.7)
(0.7)he final conversion to open repair was performed at 45
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August 2011310 Jim et almonths during a secondary endovascular intervention to
treat a distal type I endoleak (distal to the Renu main body
extension). Rupture of the external iliac artery occurred
during advancement of iliac limbs through difficult access
anatomy. The patient died following the emergent conver-
sion to open repair. The Kaplan-Meier 55-month estimated
freedom from conversion is 93.8% (Fig 2).
Death. A total of 44 deaths have been reported in the
registry cohort. These included one intraoperative death,
one early (30 days) death, and 42 late (30 days) deaths.
All deaths were reviewed by the CEC, and three have been
adjudicated as procedure-related and two as Renu-related
(Table III).
Among the three procedure-related deaths, one occurred
intraoperatively when the patient failed to recover after con-
version to open repair following rupture of the aorta proximal
to the Renu device. In the second procedure-related death,
hematologic complications occurred approximately 2 weeks
after Renu implantation. This patient was treated with a Renu
graft on an emergent basis after being hospitalized due to
aneurysm rupture and low platelet count. The third proce-
dure-related death occurred 10 months after Renu implanta-
Table II. Conversion to open repair in patients treated wi
Months Reason for conversion
0a Rupture of aortic wall proximal to Renu de
0a Persistent proximal type I endoleak
3 Persistent proximal type I endoleak
12 Type III endoleak
12 Type III endoleak
16 Type III endoleak
19 Suspected graft infection
30 Proximal type I endoleak
45 Iliac artery rupture during reintervention fo
aConversion occurred intraoperatively.
Fig 2. Kaplan-Meier curve of freedom from conversion in pa-
tients treated with a Zenith Renu AAA Ancillary Graft.tion.The cause of deathwas cardiorespiratory arrest secondary po hypotension and sepsis. In this patient, a pulmonary embo-
ism and a suspected graft infection (although blood cultures
ere negative) were identified at 4 months. The patient was
ospitalized at 7 months to drain an abdominal abscess. The
reating institution noted that the death was probably related
o an undiagnosed infection that was present prior to implan-
ation of the Renu device.
Two Renu-related deaths occurred in patients who
equired emergent conversion to open repair because of
neurysm rupture due to type III endoleak. The Kaplan-
eier estimate of freedom from aneurysm-related death is
6.6% at 55 months (Fig 3).
Migration, component separation, limb occlusion,
nd device integrity. Migration, patency, and integrity of
enu components were based upon core laboratory analy-
is. To date, there has been a single case of migration. In a
9-year-old patient, the original 28mmAneuRx device was
ound to have a 10 mm migration and a proximal type I
ndoleak at 36 months. Core laboratory analysis of the
reprocedure computed tomography demonstrated an in-
erted funnel-shaped neck measuring 30 mm just below
he lowest renal artery and 34 mm at 15 mm below the
owest renal artery. The patient was treated with a 32 mm
iameter Renu converter. No endoleaks were identified
ollowing the procedure, but migration of the Renu con-
erter 10 mm was identified at the 12-month follow-up.
o secondary interventions were performed, and the pa-
ient ultimately died of lung cancer 30 months following
enu implantation. One patient with a Renu main body
xtension underwent conversion to open repair due to
omponent separation. At the 24-month follow-up, one
ase of device occlusion was identified in a patient treated
ith a Renu converter. The site reported that an axillo-
emoral bypass was performed when the endograft became
ccluded. In addition, one case of kinking (Renu con-
erter) and one case of endograft infolding (Renu main
ody extension) have been identified. No proximal type I
r III endoleaks or occlusions have been reported for either
f these cases.
Endoleak, aneurysm enlargement, and secondary
ndovascular intervention. Prior to Renu treatment, 111
73.5%) patients were found to have endoleaks. Of the 136
ndoleaks noted in these 111 patients, 96 (63.6%) were
e Zenith Renu AAA Ancillary Graft
Rupture Death
— X
— —
— —
X —
X X
X X
— —
— —
tal type I endoleak — Xth th
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Volume 54, Number 2 Jim et al 311endoleaks, 17 (11.3%) were type II endoleaks, 10 (6.6%)
were type III endoleaks, and four (2.6%) were of unspeci-
fied or unknown type. At 1month after Renu implantation,
95 of 96 (99.0%) proximal type I endoleaks had resolved.
The patient who had the one persistent proximal type I
endoleak underwent conversion to open repair as noted
previously. All 10 type III endoleaks resolved by the
1-month follow-up. During the follow-up period, 17
(11.3%) new type I or III endoleaks were identified. These
included four proximal type I endoleaks, three distal type I
endoleaks in patients treated with a Renu converter, one
distal type I endoleak in a patient treated with a Renu main
body extension, and nine type III endoleaks. Of note, all
new type III endoleaks occurred in patients treated with a
Renu main body extension. Of the four patients with new
proximal type I endoleaks, one had an inverted funnel
shaped aortic neck, one had an inverted funnel shaped neck
and a short (2.9 mm) sealing zone between the lowest renal
artery and the proximal edge of the pre-existing graft, and a
third had a short (3.6 mm) sealing zone. The fourth case
did not have any particular high risk aortic neck character-
istic identified.
Aneurysm enlargement was defined as an increase in
Table III. Procedure- and Renu-related deaths in patients
Months Age
0a 82 Rupture of aort
1b 90 Low platelet co
10 73 Arrest from hyp
12 81 Multisystem org
16 76 Cardiac arrest fo
aDeath occurred intraoperatively.
bDeath occurred 2 weeks after Renu implantation.
Fig 3. Kaplan-Meier curve of freedom from aneurysm-related
death in patients treated with a Zenith Renu AAA Ancillary Graft.the maximum aortic diameter by 5 mm based upon amaging evaluated by the core laboratory. Aneurysm en-
argement was identified in six patients at the 12-month
ollow-up and in an additional three patients at the 24-
onth follow-up. Of these nine cases of aneurysm enlarge-
ent, seven were associated with an identified endoleak.
hese included one patient with a distal type I and type II
ndoleak, four patients with type II endoleaks, and two
atients with type III endoleaks.
As all patients in this registry had undergone previous
ndograft placement, there were instances of secondary
ndovascular interventions to treat complications related to
he original endograft. As such, there were six procedures
onsidered unrelated to the Renu component (Table IV).
owever, seven other interventions in five patients were
onsidered Renu-related (Table V). One patient was suc-
essfully treated with angioplasty and Palmaz stent place-
ent for a proximal type I endoleak of the Renu device that
as identified during routine 24-month follow-up. The
ndoleak recurred and was successfully remedied at 34
onths. Another patient had two failed endovascular treat-
ents (coil embolization at 25months and stent placement
t 29 months) for a proximal type I endoleak of the Renu
evice and subsequently underwent successful conversion
o open repair. A patient developed migration of the previ-
us endograft with development of a type III endoleak
etween the previous endograft and the Renu main body
xtension. This was successfully treated with a Renu con-
erter at 30 months. One patient had a persistent proximal
ype I endoleak of the Renu converter and was treated
uccessfully with placement of a Renu main body extension
8 months after placement of the Renu converter. In the
nal patient who underwent Renu-related secondary inter-
ention, dilatation of the distal iliac attachment site was
reated with a branched iliac endograft 44 months after
mplantation of the Renu device.
Adverse events (excluding endoleak, rupture, con-
ersion, and death). Adverse event information was re-
uested intraoperatively, at the 1-month time period, and
nnually thereafter. All events underwent medical review
nd, if necessary, were adjudicated by the CEC to deter-
ine whether the events were related to the endovascular
ntervention. If related to the endovascular intervention,
he CEC further determined whether the event was
rocedure-related, technique-related, or device-related
Renu or pre-existing graft). In total, 12 early (30 days)
ted with the Zenith Renu AAA Ancillary Graft
se of death CEC adjudication
ximal to Renu device Procedure-related
ematologic complications Procedure-related
ion/sepsis Procedure-related
ilure following rupture Renu-related
ng rupture Renu-relatedtrea
Cau
a pro
unt/h
otens
an fa
llowidverse events were reported in 11 patients, and 14 late
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August 2011312 Jim et al(30 days) adverse events were reported in 10 patients. No
adverse events have been adjudicated as technique-related
or device-related; however, nine events (in eight patients)
have been adjudicated as procedure-related (Table VI).
Clinical success. In accordance with the standards
recommended by the SVS, there were a total of 49 events
contributing to clinical failure in 32 patients. These in-
cluded the following: five deaths, 18 type I or type III
endoleaks, one graft infection, one thrombosis, nine aneu-
rysm expansions (5mm), four ruptures, nine conversions,
and one migration. The clinical success for this cohort at a
median follow-up of 45.0 months was 78.8% (119 of 151
Table IV. Secondary endovascular interventions unrelated
Month Intervention
1 Placement of additional stent
10 Placement of iliac component
12 Coil embolization
22 Placement of Zenith iliac limb graft
38 Placement of Zenith graft within original graft
45 Failed endovascular attempta
aThis patient suffered from external iliac artery rupture leading to emergent
Table V. Secondary endovascular interventions related to
Month Intervention
24a Angioplasty, Palmaz stent placement
25b Coil embolization
29b Placement of additional stent
30 Renu converter, zenith leg extension, occlude
and femoro-femoral bypass
34a Percutaneous angioplasty
38 Proximal cuff placement
44 Implantation of branched iliac endograft
aThe same patient underwent interventions at 24 months and 34 months.
bThe same patient underwent interventions at 25 months and 29 month
successful conversion to open repair at 30 months.
Table VI. Procedure-related adverse events
Month Category
Day 1 Vascular Right groin explora
Day 2 Vascular Brachial artery pseud
Day 3 Renala Serum creatinine ris
1 Vasculara Contralateral limb o
1 Wound Persistent drainage a
1 Othera Spontaneous retrop
Renala Renal failure requiri
1 Wound Groin seroma requir
4 Othera Suspected graft infe
for computed tom
died at 10 month
All events underwent medical review by the treating physician. Those even
Committee.patients). However, it merits emphasis that some of the cncluded events were related solely to the pre-existing en-
ograft and were not directly related to the Renu implant.
herefore, the calculated clinical success rate likely repre-
ents an underestimation of the real clinical outcomes re-
ated to the Renu graft. A summary of the clinical outcomes
f this registry cohort can be found in Table VII.
ISCUSSION
Since the introduction of EVAR almost two decades
go, this technique has been rapidly adopted as a viable and
ften preferred method of treating infrarenal AAAs. In
ddition to low perioperative mortality rates, data from
he Zenith Renu AAA Ancillary Graft
Reason
Graft limb occlusion on opposite side used for Renu main body
extension implantation
Distal type I endoleak in an iliac limb distal to Renu main body
extension
Type II endoleak
Type III endoleak in limb of pre-existing endograft
Type III endoleak
Distal type I endoleak in an iliac limb distal to Renu main body
extension
rsion and subsequent death.
enith Renu AAA Ancillary Graft
Reason
Proximal type I endoleak
Proximal type I endoleak
Persistent proximal type I endoleak
, Migration of pre-existing graft with type III
endoleak
Recurrent proximal type I endoleak
Proximal type I endoleak
Iliac artery dilatation at distal iliac attachment site
h interventions failed to resolve the endoleak and the patient underwent
Specific adverse event
ith revision of femoro-femoral bypass graft
urysm repair
% above baseline resulting in persistent value 2.0 mg/dL
ion requiring implantation of stents
groin incision requiring surgical intervention
eal hematoma
mporary dialysis (baseline creatinine 4.0 mg/dL)
perative debridement and closure
with negative cultures was reported at day 124; patient admitted
phy-guided drainage of an abdominal abscess at 7 months, and
rked with ( a) underwent adjudication by the independent Clinical Eventsto tthe Z
r plugtion w
oane
e 30
cclus
t the
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ts malinical trials have also demonstrated excellent long-term
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Volume 54, Number 2 Jim et al 313outcomes with 95% freedom from aneurysm-related
mortality, conversion, rupture, and migration.12-15 How-
ever, recent evidence has demonstrated the lack of long-
term survival benefits of EVAR compared with traditional
open repair.4-7 Furthermore, despite initial technical suc-
cess, the long-term durability of EVAR continues to be a
concern. Outside of the clinical trial setting, secondary
interventions to treat failing endovascular repair are
common and can be seen in 9% to 14% of patients during
follow-up.16-18
A critical complication unique to endovascular repair is
the development of proximal attachment failure with sub-
sequent development of migration and/or endoleak.19Mi-
gration has been shown to be a potential complication of all
commercially available endografts. However, the AneuRx
stent graft has typically been associated with higher migra-
tion rates than other devices. In earlier series, migration
rates of 27% to 42% at 3 years were reported.20,21 Data from
the multicenter AneuRx clinical trial showed a Kaplan-
Meier estimate of migration of 19% at 3 years.22 While the
endograft itself may be responsible for the high migration
rates, subsequent literature suggested that migration may
also be related to suboptimal aortic anatomy. In patients
who met the criteria in the IFU for the AneuRx device, the
migration rate at 4 years was only 6.1%, compared with
42.1% for patients with unfavorable neck anatomy.23
Proximal attachment failure can develop several years
after initial device implantation. When attachment failures
occur, the patients are older and often present with addi-
tional medical comorbidities not present during the initial
endovascular treatment. Because migration and proximal
endoleak can ultimately lead to aneurysm expansion, sec-
ondary interventions should be performed to prevent an-
eurysm rupture and patient death. As many of the patients
who initially underwent EVAR were considered unfit for
traditional open repair, any means of salvaging the failed
EVAR in an endovascular fashion may be the best option
for these patients. The use of proximal aortic cuffs has been
reported for the treatment of proximal attachment failures;
however, the technical and clinical success rates of cuff
placement remain in question.24-27
The Zenith Renu AAA Ancillary Graft, which received
FDA approval in 2005, was designed as a “bailout” device
Table VII. Clinical outcomes of the Zenith Renu AAA
Ancillary Graft
Category Outcome
Deployment success 100%
Technical success 98.0%
Freedom from aneurysm-related mortalitya 96.6%
Freedom from conversiona 93.8%
Freedom from rupturea 97.3%
Clinical successb 78.8%
aKaplan-Meier estimates at 55 months.
bAt a median follow-up of 45.0 months.for endovascular salvage of endografts with failed or failing uroximal fixation. In this study, data obtained from a
ostmarket registry were used to evaluate clinical outcomes
f the Renu graft. The vast majority (80%) of patients
reated for proximal fixation failure had previous implanta-
ion of the AneuRx device. Furthermore, reinforcing the
oncern about long-term failure of endovascular repair, the
atients who had proximal graft failures necessitating treat-
ent had a median interval of 41.0 months between the
riginal graft placement and the Renu graft placement.
The Renu device has two configurations that allow the
hysician to treat patients depending on patient-specific
natomic factors. Both configurations have a stable transre-
al attachment with active fixation along with a proximal
ealing stent designed to seal type I endoleaks. This feature
istinguishes the main body extension device from other
roximal aortic cuffs. The converter device has an addi-
ional distal component which extends into the iliac artery
o create an AUI repair. While the use of this configuration
s more labor intensive, the femoro-femoral bypass associ-
ted with AUI repair has been shown to be durable with
xcellent long-term patency rates.28,29 While the IFUs for
oth configurations are similar, there are certain anatomic
eatures that favor the use of the converter device. When a
ain body extension is utilized, aneurysm exclusion is still
eliant upon proper functioning of the pre-existing en-
ograft. As demonstrated in the three patients that devel-
ped aneurysm rupture from a type III endoleak, a cuff
laced in an angulated neck can separate from the pre-
xisting endograft from the forces pushing on the compo-
ents.
The literature on the use of aortic cuffs to treat mi-
rated endografts remains limited. In a single-center retro-
pective series of 20 patients with proximal attachment
ailure from an AneuRx device, 14 of 16 were successfully
reated at 1-year follow-up with an aortic cuff.25 However,
later series of 23 patients from two institutions showed
hat 26% had failed secondary reconstruction at 14 months
f follow-up.26 In a series of 42 patients that underwent
ndovascular revision of their failed EVAR, proximal cuffs
ere successful in only 45% of the patients, while the use of
n AUI device allowed for successful repair in 86% of
ases.27 A previous report of the short-term data from this
egistry suggested that the converter configuration was the
etter reconstructive option compared with the main body
xtension.10 While the comparison between the two con-
gurations was not repeated during this study, further
nalyzes are pending to evaluate this variable, as well as
ther factors, as follow-up for patients in this registry is
ngoing.
Limitations. The Zenith Renu AAA Ancillary Graft is
sed to treat failing or failed pre-existing endovascular
epairs. As such, the operative as well as imaging details of
he prior endograft implantation may provide valuable in-
ight into patient outcomes. As this registry was intended
nly to focus on the outcomes of treatment with the Renu
evice, details regarding the prior endograft treatment were
ot always available. Although every case in this registry
nderwent evaluation by a member of the physician review
R1
1
1
1
1
1
1
1
1
1
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August 2011314 Jim et alcommittee, the choice of final device configuration was left
to the discretion of the treating physician. There were
multiple instances in which the implanted device was dif-
ferent from the recommendation of the committee. In
cases of adverse events, it remains unclear whether the use
of the recommended device configuration would have led
to different clinical outcomes. Furthermore, there is no
control group available, as comparison to alternative treat-
ments is not an aim of this registry.
CONCLUSION
The Zenith Renu AAA Ancillary Graft registry data
demonstrate that the Renu device was easy to use with
successful deployment in all cases. The technical success
rate was high (98.0%) with only two cases of intraoperative
conversion and one persistent endoleak. In midterm follow-
up of over 3 years, the clinical outcomes also suggest that
the Renu device is a safe and viable endovascular recon-
struction option for patients with proximal failure and/or
graft migration. The Renu graft has shown good midterm
device integrity with only one instance of device occlusion
and no other clinically significant events. The Kaplan-Meier
estimates at 55 months for freedom from rupture, conver-
sion, and aneurysm-related mortality were 97.3%, 93.8%,
and 96.6%, respectively. These outcomes are comparable to
those seen in other multicenter device trials of original
endovascular treatments.12-15 In fact, these results become
even more impressive when it is understood that patients in
this registry clearly represent a cohort with challenging
anatomy in which endovascular repair has already failed.
While endovascular salvage is possible in almost four out of
five patients at midterm follow-up as reported in this study,
these results emphasize the importance of proper patient
selection, accurate device deployment, and the need for
diligent postimplantation surveillance after initial endovas-
cular aneurysm repair.
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Graft.
Indication Main
Length 43 mm from th
bifurcation of
Distal fixation Within a graft se
and 17 mm
length, with m
preferred
Both configurations require the following:
aortic fixation site diameter to be
between 18 and 32 mm (measured
outer wall to outer wall); angle 60
degrees relative to the long axis of the
aneurysm; angle 45 degrees relative to
the axis of the suprarenal aorta;
adequate femoral/iliac access
compatible with the required
introduction systemsthe instruction for use of the Zenith Renu AAA Ancillary
body extension Converter
e lowest renal artery to
pre-existing endograft
37 mm from the lowest renal artery
to bifurcation of pre-existing
endograft
gment 34 mm diameter
(1 Cook Z-stent) in
ore overlap length being
If used without an iliac leg, within a
graft segment 12 mm diameter
and 17 mm in length, with more
overlap length being preferred
If used in combination with the iliac
leg, 7.5-20 mm in diameter
(measured outer wall to outer wall)
and 10 mm in length, with 20-
30 mm being preferred
